https://www.creativebiomart.net/ctla4biotinylatedb7-2-inhibitor-screening-assay-kit-465598.htm
Cat.No.: | Kit-1713 |
Product Overview: | B7-2 (CD86) signaling through CTLA4(CD152) has been shown to inhibit T cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host"s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer. |